For reconstitution procedures, see our reconstitution guide
TB-500 is studied for actin sequestration, cytoskeletal dynamics, and ILK-AKT cell-survival signaling, which influence cell migration and wound closure
Assess Operational History: Favor suppliers with 5+ years of operation for proven stability
Dosing, Administration, and Best Practices Recommended Dosing Protocols Dosing for BPC-157 TB-500 nasal spray varies based on individual goals, body weight, and the specific concentration of the formulation: Typical BPC-157 Dosing Maintenance: 250-500 mcg per day Active recovery: 500-750 mcg per day Acute injury: 750-1000 mcg per day (divided doses) Typical TB-500 Dosing Maintenance: 2-2.5 mg twice weekly Loading phase: 5-10 mg weekly (first 4-6 weeks) Maintenance phase: 2-5 mg weekly thereafter Combined Nasal Spray Formulations often provide both peptides in ratios designed for convenient once or twice-daily administration
Retatrutide Phase 3 trial protocol: weekly titration from 1mg to 12mg
They isolated it, synthesized it, and called it BPC-157